Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
LUND, Sweden, Feb. 18, 2016 --
Laquinimod
- In April, it was announced that the first patient was enrolled to ARPEGGIO, which is evaluating laquinimod's potential for treatment of primary progressive multiple sclerosis (PPMS)
- In June, it was announced that the company was to focus its operations on the laquinimod projects and adjust the organization accordingly
- In June, it was announced that the Phase 3 laquinimod study CONCERTO was fully enrolled
- In October, Teva presented data concerning laquinimod for the treatment of multiple sclerosis at the ECTRIMS congress
- The high dose group in the clinical studies CONCERTO, ARPEGGIO and LEGATO has been discontinued due to cardiovascular events
- The study results from both the pivotal clinical Phase 3 study CONCERTO in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017
Tasquinimod
- In April, it was announced that Active Biotech and Ipsen were to discontinue development of tasquinimod for the treatment of prostate cancer
- The final results from the 10TASQ10 study were presented in September 2015 at the ECC conference and demonstrated that while the primary endpoint was reached and tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS
ANYARA, Paquinimod (57-57) and ISI
- Out-licensing activities are continuing
Financial summary
| MSEK | Oct - Dec | Jan. - Dec. | ||||
| 2015 | 2014 | 2015 | 2014 | |||
| Net sales | 5.0 | 2.9 | 16.3 | 10.4 | ||
| Operating loss | -28.2 | -55.6 | -177.9 | -228.5 | ||
| Loss for the period | -40.8 | -57.0 | -193.5 | -231.5 | ||
| Loss per share, before and after dilution (SEK) | -0.45 | -0.73 | -2.15 | -3.02 | ||
| Cash and cash equivalents | 103.6 | 328.5 | ||||
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
The report is also available at www.activebiotech.com.
Active Biotech AB Year-end report January - December 2015 http://hugin.info/1002/R/1986986/729147.pdf
HUG#1986986
